Beroni Group Published an Article Related to Single-Domain Antibodies in the FEBS Journal

Rhea-AI Summary

Beroni Group (OTCQX: BNIGF) has announced the acceptance of its article on SARS-CoV-2 nucleocapsid protein for publication in the FEBS Journal. This work details the identification of two crystal structures of the protein, which is essential for viral RNA packing and infection. The company has discovered four single-domain antibodies (sdAbs) that target various nucleocapsid protein regions, showing potential for future diagnostic and therapeutic applications. Beroni aims to further this research into clinical trials to aid in combating COVID-19.

Positive

• Article on SARS-CoV-2 nucleocapsid protein accepted for publication in a peer-reviewed journal.
• Identification of four sdAbs with high affinities targeting the nucleocapsid protein, indicating potential for diagnostic and therapeutic use.
• Plans to progress research into clinical trials for COVID-19 detection and treatment.

Negative

• None.

NEW YORK and SYDNEY, Australia, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based biopharmaceutical enterprise, today announced that its article entitled “Crystal structures of the SARS-CoV-2 nucleocapsid protein C-terminal domain and development of nucleocapsid-targeting nanobodies” has been accepted for publication and undergone full review in the FEBS Journal. The full article can be viewed at https://febs.onlinelibrary.wiley.com/doi/epdf/10.1111/febs.16239.

The FEBS Journal is an international peer-reviewed non-profit society journal devoted to publishing high-quality papers reporting significant advances in the molecular life sciences.

The published article is related to the scientific findings derived from Beroni’s current research of the development of a medical solution using single-domain antibodies (sdAbs) for the SARS-CoV-2 coronavirus. The Company has identified 2 crystal structures of nucleocapsid protein C-terminal domain. Nucleocapsid protein is a major structural protein of SARS-CoV-2 and plays an important role in viral RNA packing, replication, assembly, and infection. Through screening a sdAbs library, the scientific team has identified four sdAbs targeting different regions of nucleocapsid protein with high affinities that have future potential to be used in viral detection and therapeutic purposes.

“We are delighted to progress further in our coronavirus research program and to publish our new findings in the FEBS journal. The Company plans to carry out a series of experiments to gradually transform the results into clinical trials and find a new way for the diagnosis and treatment of the new coronavirus. Beroni hopes our efforts can contribute to the basic understanding of the SARS-CoV-2 coronavirus and the global development of antiviral drugs.” said Jacky Zhang, Chairman and CEO of Beroni Group.

About Beroni Group Limited

Beroni Group is an Australia-based biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia and traded on the OTC markets in the USA. To learn more about Beroni, please visit www.beronigroup.com.

Forward-Looking Statements Disclaimer
This press release contains forward-looking statements or forward-looking information, within the meaning of applicable United States and Australian securities laws with respect to the Company. By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Generally forward-looking statements can be identified by the use of terminology such as “anticipate”, “will”, “expect”, “may”, “continue”, “could”, “estimate”, “forecast”, “plan”, “intend”, “believe”, “potential” and similar expressions.

Forward-looking information contained in this press release is based on Company management’s opinions, estimates and assumptions in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward-looking statements involve significant risks, uncertainties and assumptions, and there can be no assurance that such statements, or its underlying risks, uncertainties and assumptions will prove to be accurate. Factors that could cause actual results or events to differ materially include, without limitation, risks related to laws, rules and regulation applicable to the Company as well as the industry in which it operates (including in respect of taxes and other levies), economic or market conditions on both a national and global level, currency fluctuations, risks inherent to other entities at a similar stage of development and industry in which the Company currently is, competition from the Company’s competitors, unsatisfactory development or marketing of the Company and/or its products or services, regulatory action or litigation (including product liability claims), and failure to enter into agreements or arrangements with other parties on fair or reasonable terms. Forward-looking information is made only as of the date on which it is provided and, except as may be required by applicable laws, the Company disclaims any intent or obligation to update such forward-looking information whether as a result of new information, future events or otherwise.

For more information, please contact our IR consultants at:

Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: BNIGF@dgipl.com

FAQ

What is the significance of the research published by Beroni Group in the FEBS Journal?

The research identifies two crystal structures of the SARS-CoV-2 nucleocapsid protein and discovers four single-domain antibodies (sdAbs) that target it, which may lead to advancements in COVID-19 diagnostics and therapeutics.

How does Beroni Group plan to use its research findings on SARS-CoV-2?

Beroni Group intends to conduct a series of experiments to transition their findings into clinical trials for potential COVID-19 diagnosis and treatment solutions.

What types of antibodies were discovered in Beroni's latest research?

The company identified four single-domain antibodies (sdAbs) targeting different regions of the nucleocapsid protein with high affinities.

When was the press release issued regarding Beroni Group's research publication?

The press release was issued on October 28, 2021.

What is the stock symbol for Beroni Group?

The stock symbol for Beroni Group is BNIGF.